Labviva Secures $25M Series B Funding to Enhance AI-Powered Life Sciences Procurement Platform

Labviva Secures $25M in Series B Funding

Labviva, the leading AI procurement platform for life sciences, has successfully closed a $25 million Series B funding round, bringing its total funding to $55 million. The investment was led by 53 Stations, with continued participation from Biospring Partners, B Capital Group, and Glasswing Ventures 1

1

2

Rapid Growth and Expansion Plans

Over the past year, Labviva has demonstrated impressive growth, doubling its revenue and tripling transactions on its platform. The company plans to utilize the new funding to:

1. Accelerate new product development
2. Bolster marketing and customer support efforts
3. Expand internationally

As part of the fundraising, Jason Pritzker, Co-Founder and Managing Partner of 53 Stations, will join Labviva's Board of Directors 1

1

AI-Powered Solutions for Life Sciences

Labviva's platform leverages artificial intelligence to connect suppliers, purchasing departments, and scientists, streamlining the procurement process for life science research. The company's technology offers several key benefits:

1. Supply chain transparency
2. Automated purchasing management
3. Efficient inventory replenishment
4. Access to a diverse pool of suppliers, including major vendors and small, local, and green-certified businesses

By aggregating 90% of all life science suppliers, Labviva enables customers to quickly compare products and prices, potentially saving hours of manual research and reducing R&D costs 1

1

2

Market Potential and Industry Adoption

The use of AI in life sciences is forecasted to reach $11 billion by 2033, primarily driven by pharmaceutical and biotech adoption. According to MIT Technology Review Insights, the life sciences sector has "gone all in on AI," with major pharmaceutical companies implementing AI across various business processes 1

1

Related Stories

Lila Sciences Secures $115M Funding, Valuation Soars to $1.3B with Nvidia Backing

LogicFlo AI Secures $2.7M Seed Funding to Revolutionize Life Sciences with AI Agents

Lila Sciences Raises $200M to Revolutionize Scientific Discovery with AI

Latent Labs Emerges with $50M to Revolutionize Drug Discovery Using AI

Integration and Compatibility

Labviva's platform is designed to operate as a stand-alone solution or integrate directly into leading procurement systems, including:

• SAP Ariba
• JAGGAER
• Oracle Procurement Cloud
• Microsoft Dynamics 365
• Coupa

This flexibility allows for seamless adoption within existing corporate infrastructures 1

1

Leadership Perspective

Siamak Baharloo, CEO & Co-Founder of Labviva, expressed optimism about the company's future: "We've been laser focused on building close customer and supplier relationships and deploying solutions that drive instant, long-term results. This strategy paid off because today, we've reached an inflection point that positions Labviva for massive growth" 1

1

2

As Labviva continues to expand its AI-powered procurement solutions, the company is poised to play a significant role in accelerating life science research and enhancing supply chain efficiency in the biopharma industry.